Is Indaptus Therapeutics Stock a good buy in 2025, according to Wall Street analysts?
The consensus among 1 Wall Street analyst covering (NASDAQ: INDP) stock is to Strong Buy INDP stock.
Out of 1 analyst, 1 (100%) are recommending INDP as a Strong Buy, 0 (0%) are recommending INDP as a Buy, 0 (0%) are recommending INDP as a Hold, 0 (0%) are recommending INDP as a Sell, and 0 (0%) are recommending INDP as a Strong Sell.
What is INDP's earnings growth forecast for 2025-2025?
(NASDAQ: INDP) Indaptus Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of N/A, and while it is not forecast to beat the US market's average forecast earnings growth rate of N/A.
Indaptus Therapeutics's earnings in 2025 is -$15,022,027.
In 2025, INDP is forecast to generate -$19,912,357 in earnings, with the lowest earnings forecast at -$19,912,357 and the highest earnings forecast at -$19,912,357.
What is INDP's forecast return on equity (ROE) for 2025-2025?
(NASDAQ: INDP) forecast ROE is -504.77%, which is considered weak.
What is INDP's Price Target?
According to 1 Wall Street analyst that have issued a 1 year INDP price target, the average INDP price target is $5.00, with the highest INDP stock price forecast at $5.00 and the lowest INDP stock price forecast at $5.00.
The Wall Street analyst predicted that Indaptus Therapeutics's share price could reach $5.00 by Nov 13, 2025. The average Indaptus Therapeutics stock price prediction forecasts a potential upside of 986.96% from the current INDP share price of $0.46.
What is INDP's Earnings Per Share (EPS) forecast for 2025-2025?
(NASDAQ: INDP) Indaptus Therapeutics's current Earnings Per Share (EPS) is -$1.61. In 2025, INDP's EPS is forecast to hit -$1.38 (min: -$1.38, max: -$1.38).
What is INDP's forecast return on assets (ROA) for 2025-2025?
(NASDAQ: INDP) forecast ROA is -271.33%, which is lower than the forecast US Biotechnology industry average of 84.94%.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.